NCT04204850 is a Phase 2 clinical trial of Cabozantinib in Hepatocellular Carcinoma, sponsored by University Health Network, Toronto.

Who is sponsoring NCT04204850?

NCT04204850 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT04204850?

Interventions in NCT04204850: Cabozantinib.

What condition does NCT04204850 study?

NCT04204850 studies Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant.

Is NCT04204850 still recruiting?

NCT04204850 is currently recruiting now. Last updated 3 December 2025.

Last reviewed 2025-12-03 · How we verify

NCT04204850

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Recruiting now Phase 2 Last updated 3 December 2025

What this trial tests

Phase 2 trial testing Cabozantinib in Hepatocellular Carcinoma in 20 participants. Currently enrolling.

Timeline

7 August 2020

Primary endpoint
1 June 2026

30 June 2026

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	7 August 2020
Primary completion	1 June 2026
Estimated completion	30 June 2026
Sites	1 location across Canada

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Recurrent Cancer — all drugs for Recurrent Cancer →
Liver Transplant — all drugs for Liver Transplant →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Hepatocellular Carcinoma or Recurrent Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how useful cabozantinib is in controlling the disease of these patients. Cabozantinib blocks the function of various proteins found on the surface of the body's cells (called receptor tyrosine kinases) that are important in the development of cancer tumors. All participants will receive cabozantinib until they are no longer receiving benefit from the study drug or they experience an intolerable side effect.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
Chan YT, Zhang C, Wu J, Lu P, et al · · 2024 · cited 158× · PMID 39242496 · DOI 10.1186/s12943-024-02101-z
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
Tümen D, Heumann P, Gülow K, Demirci CN, et al · · 2022 · cited 111× · PMID 36551958 · DOI 10.3390/biomedicines10123202
BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8
Frontline therapy for advanced hepatocellular carcinoma: an update.
Akce M, El-Rayes BF, Bekaii-Saab TS. · · 2022 · cited 22× · PMID 35432597 · DOI 10.1177/17562848221086126
AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.
Hsu CH, Huang YH, Lin SM, Hsu C. · · 2022 · cited 21× · PMID 35634427 · DOI 10.1159/000520501
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
Trojan J. · · 2020 · cited 20× · PMID 32671719 · DOI 10.1007/s40265-020-01361-5
Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma.
Liang J, Bai Y, Ha FS, Luo Y, et al · · 2023 · cited 11× · PMID 36684055 · DOI 10.4251/wjgo.v15.i1.1
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.
Vandewalle N, De Beule N, De Becker A, De Bruyne E, et al · · 2024 · cited 7× · PMID 39367387 · DOI 10.1186/s40164-024-00566-8

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04204850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 3 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04204850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing